Phase III study evaluating palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with hormone receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy.
Disease site: Breast cancer
Treatment modality: Systemic therapy (palbociclib)
Status: In follow up
PENELOPEB is a phase III international, multicentre, randomised, placebo-controlled, double-blind trial comparing the efficacy and safety of adding palbociclib to standard hormone therapy vs standard hormone therapy alone for the treatment of breast cancer patients with an increased risk of relapse after having received chemotherapy prior surgery.
In total 1,100 women from 13 countries are expected to take part. In the UK, 35 patients will be recruited over a two-year period. Participants will be randomised to one of two treatment groups:
- Palbociclib + standard hormone therapy; or
- Placebo + standard hormone therapy.
Participants will receive trial treatment for one year and will continue to receive standard hormone therapy for a total of at least five years.
UK Coordinating Investigator: Dr Andreas Makris (East and North Hertfordshire NHS Trust)
ICR-CTSU Scientific Lead: Professor Judith Bliss
Trial management contact: [email protected]
ClinicalTrials.gov identifier: NCT01864746
Sponsor: German Breast Group (GBG)
View PENELOPE-B on the UK Clinical Trials Gateway
A link to a plain English summary of the trial will be added once available.
The German Breast Group (GBG) website provides information on PENELOPEB in German.
Publications and presentations
There have been no presentations or publications to date.